Raffaele Colombo/LinkedIn
May 15, 2025, 11:42
Raffaele Colombo Highlights IND Approval of VEGF-Targeting ADC YL242
Raffaele Colombo, Associate Director, Medicinal Chemistry at Zymeworks Inc., shared on X about a recent paper by Tongtong Xue et al. published in AACR Journals:
“IND approved by Chinese NMPA for YL242, a non-internalizing ADC targeting soluble VEGF, with a TOPO1i payload, and DAR=4.
They recently presented a poster on its preclinical development at AACR25 in Chicago.”
Title: Abstract 3140: Preclinical development of YL242, a non-internalized antibody-drug conjugate (ADC) targeting soluble VEGF for treatment of solid tumors
Authors: Tongtong Xue, Wei Lian, Qing Zong, Chun Deng, Qigang Liu, Peng Zou, Jiaqiang Cai
More posts featuring Raffaele Colombo.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 26, 2025, 21:46
Jul 26, 2025, 21:30
Jul 26, 2025, 21:09
Jul 26, 2025, 20:53
Jul 26, 2025, 20:13
Jul 26, 2025, 16:51